지연성 운동장애 치료 시장 규모, 점유율, 성장 분석 : 치료법별, 약물별, 투여 경로별, 최종사용자별, 유통 채널별, 지역별 - 업계 예측(2026-2033년)

Global Tardive Dyskinesia Treatment Market size was valued at USD 3.88 Billion in 2024 and is poised to grow from USD 4.18 Billion in 2025 to USD 7.63 Billion by 2033, growing at a CAGR of 7.8% during the forecast period (2026-2033).

The global tardive dyskinesia treatment market is poised for growth driven by the rising prevalence of psychiatric disorders like schizophrenia and bipolar disorder, which often necessitate long-term antipsychotic treatment, leading to tardive dyskinesia. Advances in VMAT2 Inhibitor therapies and regulatory support for accelerated approvals further enhance market potential. Increased healthcare infrastructure in emerging economies is facilitating better access to neurological and psychiatric care, while growing awareness of tardive dyskinesia is promoting treatment adoption. However, challenges such as high treatment costs, potential adverse side effects of existing therapies, low awareness in developing regions, and limited research and development investment due to a small patient population may hinder market expansion in the foreseeable future.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Tardive Dyskinesia Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Tardive Dyskinesia Treatment Market Segments Analysis

Global Tardive Dyskinesia Treatment Market is segmented by Treatment, Drugs, Route of administration, End User, Distribution Channel and region. Based on Treatment, the market is segmented into Medication and Surgery. Based on Drugs, the market is segmented into Antipsychotics, VMAT2 Inhibitors, Botulinum Toxin, Natural Remedies, Dopamine-Depleting Medications and Others. Based on Route of administration, the market is segmented into Oral and Injectable. Based on End User, the market is segmented into Hospitals, Homecare, Specialty Clinics and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Tardive Dyskinesia Treatment Market

The Global Tardive Dyskinesia Treatment market is significantly driven by the proactive measures taken by regulatory authorities, particularly in facilitating faster approval processes for new therapies aimed at addressing the unmet medical needs associated with this condition. These expedited pathways, which include fast-track designations and priority reviews, encourage pharmaceutical companies to pursue the development of innovative treatments. As a result, this regulatory support not only enhances the likelihood of rapid market entry for promising drug candidates but also positively influences the overall outlook for the global tardive dyskinesia treatment market by stimulating investment and innovation in this critical area of healthcare.

Restraints in the Global Tardive Dyskinesia Treatment Market

The Global Tardive Dyskinesia Treatment market faces notable challenges due to the side effects associated with VMAT2 inhibitors, which are commonly used to manage this condition. Patients often experience fatigue, depression, and somnolence, significantly affecting their adherence to treatment regimens and overall quality of life. These adverse effects can lead to some patients opting to discontinue their therapy altogether. Furthermore, healthcare providers may exhibit reluctance in prescribing these medications due to concerns regarding their long-term safety profiles. Consequently, these factors collectively contribute to a slower adoption of effective treatment options for tardive dyskinesia.

Market Trends of the Global Tardive Dyskinesia Treatment Market

The Global Tardive Dyskinesia Treatment market is witnessing a significant trend driven by advancements in VMAT2 inhibitor therapies. The emergence of medications like valbenazine and deutetrabenazine has transformed the treatment landscape, offering targeted relief from the symptoms of tardive dyskinesia with enhanced efficacy and safety. Innovative formulations, such as Ingrezza Sprinkle, further address patient needs, specifically those with swallowing difficulties, thereby improving treatment adherence and overall outcomes. This focus on developing sophisticated and patient-centric therapies positions VMAT2 inhibitors as a cornerstone of the market, suggesting a future trend towards more effective and accessible treatment options for this challenging condition.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies

Global Tardive Dyskinesia Treatment Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Medication
• Surgery

Global Tardive Dyskinesia Treatment Market Size by Drugs & CAGR (2026-2033)

• Market Overview
• Antipsychotics
• VMAT2 Inhibitors
• Botulinum Toxin
• Natural Remedies
• Dopamine-Depleting Medications
• Others

Global Tardive Dyskinesia Treatment Market Size by Route of administration & CAGR (2026-2033)

• Market Overview
• Oral
• Injectable

Global Tardive Dyskinesia Treatment Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Homecare
• Specialty Clinics
• Others

Global Tardive Dyskinesia Treatment Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Others

Global Tardive Dyskinesia Treatment Market Size & CAGR (2026-2033)

• North America (Treatment, Drugs, Route of administration, End User, Distribution Channel)
  • US
  • Canada
• Europe (Treatment, Drugs, Route of administration, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment, Drugs, Route of administration, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment, Drugs, Route of administration, End User, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment, Drugs, Route of administration, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Neurocrine Biosciences, Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• H. Lundbeck A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Holdings Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch Health Companies Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sumitomo Pharma America, Inc (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Reviva Pharmaceuticals Holdings, Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acadia Pharmaceuticals Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• VANDA PHARMACEUTICALS (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Group (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lilly (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mallinckrodt (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations